ARS1620

ARS1620

CAT N°: 27915
Price:

From 177.00 150.45

ARS1620 is a covalent inhibitor of K-RASG12C (IC50 = G12C (IC50s = 150 nM) over H441, A549, and HCT116 cells expressing wild-type K-RAS (IC50s = >10 ?M). ARS1620 (200 mg/kg) induces tumor regression in a MIA-PaCa2, but not an H441, mouse xenograft model. It also decreases tumor volume in patient-derived xenograft (PDX) mouse models expressing K-RASG12C, but not K-RASG12D or wild-type K-RAS.

Territorial Availability: Available through Bertin Technologies only in France

  • Synonyms
    • 1-[4-[(7S)-6-chloro-8-fluoro-7-(2-fluoro-6-hydroxyphenyl)-4-quinazolinyl]-1-piperazinyl]-2-propen-1-one
  • Correlated keywords
    • KRASG12C ARS-1620 KRAS-G12C G-12C H-358 MIAPaCa2 MIAPaCa-2 LU-65 H-441 A-549 HCT-116 KRASG12D G12D WT
  • Product Overview:
    ARS1620 is a covalent inhibitor of K-RASG12C (IC50 = G12C (IC50s = 150 nM) over H441, A549, and HCT116 cells expressing wild-type K-RAS (IC50s = >10 ?M). ARS1620 (200 mg/kg) induces tumor regression in a MIA-PaCa2, but not an H441, mouse xenograft model. It also decreases tumor volume in patient-derived xenograft (PDX) mouse models expressing K-RASG12C, but not K-RASG12D or wild-type K-RAS.

We also advise you